Suppression of hepatitis C virus genome replication in cells with RNA-cleaving DNA enzymes and short-hairpin RNA

Oligonucleotides

Volumn 20, Issue 6, 2010, Pages 285-296

  Lee, Bokhui ^a   Bo Kim, Kyung ^a   Oh, Sangtaek ^b   Sig Choi, Joon ^c   Park, Jong Sang ^d   Min, Dal Hee ^e   Kim, Dong Eun ^a  

^a Konkuk University   (South Korea)

^b Inje University   (South Korea)

^c Chungnam National University   (South Korea)

^d Seoul National University   (South Korea)

^e Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HELICASE; PROTEINASE; SHORT HAIRPIN RNA; VIRUS DNA; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DNA LIBRARY; DNA SCREENING; GENE POOL; GENE TARGETING; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REPLICON; RNA CLEAVAGE; VIRUS GENOME; VIRUS REPLICATION;

BASE SEQUENCE; CELL LINE, TUMOR; DNA, CATALYTIC; GENOME, VIRAL; HEPACIVIRUS; HUMANS; HYDROLYSIS; MOLECULAR SEQUENCE DATA; RNA, VIRAL; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 78650397625     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2010.0256     Document Type: Article

References (51)

1. BARTENSCHLAGER, R., AHLBORN-LAAKE, L., MOUS, J., and JACOBSEN, H. (1993). Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol. 67, 3835-3844.
2. BARTENSCHLAGER, R., FRESE, M., and PIETSCHMANN, T. (2004). Novel insights into hepatitis C virus replication and persistence. Adv. Virus Res. 63, 71-180.
3. BARTOLOME, J., CASTILLO, I., and CARRENO, V. (2004). Ri-bozymes as antiviral agents. Minerva Med. 95, 11-24.
4. BIRIKH, K.R., BERLIN, Y.A., SOREQ, H., and ECKSTEIN, F. (1997). Probing accessible sites for ribozymes on human ace-tylcholinesterase RNA. RNA 3, 429-437.
5. CAIRNS, M.J., HOPKINS, T.M., WITHERINGTON, C., WANG, L., and SUN, L.Q. (1999). Target site selection for an RNA-cleaving catalytic DNA. Nat. Biotechnol. 17, 480-486.
6. CHOI, B.R., GWAK, J., KWON, H.M., OH, S., KIM, K.P., CHOI, W.H., CHO, Y.H., and KIM, D.E. (2010). Oligodeoxyriboz-ymes that cleave {beta}-catenin messenger RNA inhibit growth of colon cancer cells via reduction of {beta}-catenin response transcription. Mol. Cancer Ther. 9, 1894-1902.
7. CHOI, J.S., NAM, K., PARK, J.Y., KIM, J.B., LEE, J.K., and PARK, J.S. (2004). Enhanced transfection efficiency of PA-MAM dendrimer by surface modification with L-arginine. J. Control. Release 99, 445-456.
8. CHOO, Q.L., RICHMAN, K.H., HAN, J.H., BERGER, K., LEE, C., DONG, C., GALLEGOS, C., COIT, D., MEDINA-SELBY, R., BARR, P.J., et al. (1991). Genetic organization and diversity of the hepatitis C virus. Proc. Natl. Acad. Sci. USA 88, 2451-2455.
9. DASS, C.R., CHOONG, P.F., and KHACHIGIAN, L.M. (2008). DNAzyme technology and cancer therapy: cleave and let die. Mol. Cancer Ther. 7, 243-251.
10. GRAKOUI, A., MCCOURT, D.W., WYCHOWSKI, C., FEIN-STONE, S.M., and RICE, C.M. (1993). A second hepatitis C virus-encoded proteinase. Proc. Natl. Acad. Sci. USA 90, 10583-10587.
11. HAAS, T., METZGER, J., SCHMITZ, F., HEIT, A., MULLER, T., LATZ, E., and WAGNER, H. (2008). The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity 28, 315-323.
12. HEALE, B.S., SOIFER, H.S., BOWERS, C., and ROSSI, J.J. (2005). siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res. 33, e30.
13. HIJIKATA, M., MIZUSHIMA, H., AKAGI, T., MORI, S., KA-KIUCHI, N., KATO, N., TANAKA, T., KIMURA, K., and SHIMOTOHNO, K. (1993). Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J. Virol. 67, 4665-4675.
14. HO, S.P., BAO, Y., LESHER, T., MALHOTRA, R., MA, L.Y., FLUHARTY, S.J., and SAKAI, R.R. (1998). Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat. Biotechnol. 16, 59-63.
15. HO, S.P., BRITTON, D.H., STONE, B.A., BEHRENS, D.L., LEF-FET, L.M., HOBBS, F.W., MILLER, J.A., and TRAINOR, G.L. (1996). Potent antisense oligonucleotides to the human multi-drug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res. 24, 1901-1907.
16. HOOFNAGLE, J.H. (2002). Course and outcome of hepatitis C. Hepatology 36, S21-S29.
17. KATO, N., HIJIKATA, M., OOTSUYAMA, Y., NAKAGAWA, M., OHKOSHI, S., SUGIMURA, T., and SHIMOTOHNO, K. (1990). Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc. Natl. Acad. Sci. USA 87, 9524-9528.
18. KRETSCHMER-KAZEMI FAR, R., and SCZAKIEL, G. (2003). The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res. 31, 4417-4424.
19. KUMAR, D., CHAUDHURY, I., KAR, P., and DAS, R.H. (2009). Site-specific cleavage of HCV genomic RNA and its cloned core and NS5B genes by DNAzyme. J. Gastroenterol. Hepatol. 24, 872-878.
20. LIMA, W.F., BROWN-DRIVER, V., FOX, M., HANECAK, R., and BRUICE, T.W. (1997). Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J. Biol. Chem. 272, 626-638.
21. LOHMANN, V., KORNER, F., DOBIERZEWSKA, A., and BARTENSCHLAGER, R. (2001). Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J. Virol. 75, 1437-1449. (Pubitemid 32094702)
22. LOVE, R.A., PARGE, H.E., WICKERSHAM, J.A., HOSTOMSKY, Z., HABUKA, N., MOOMAW, E.W., ADACHI, T., and HOSTOMSKA, Z. (1996). The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87, 331-342.
23. LU, Z.X., YE, M., YAN, G.R., LI, Q., TANG, M., LEE, L.M., SUN, L.Q., and CAO, Y. (2005). Effect of EBV LMP1 targeted DNAzymes on cell proliferation and apoptosis. Cancer Gene Ther. 12, 647-654.
24. LUO, K.Q., and CHANG, D.C. (2004). The gene-silencing efficiency of siRNA is strongly dependent on the local structure of mRNA at the targeted region. Biochem. Biophys. Res. Commun. 318, 303-310.
25. MANABE, S., FUKE, I., TANISHITA, O., KAJI, C., GOMI, Y., YOSHIDA, S., MORI, C., TAKAMIZAWA, A., YOSIDA, I., and OKAYAMA, H. (1994). Production of nonstructural proteins of hepatitis C virus requires a putative viral protease encoded by NS3. Virology 198, 636-644.
26. MATVEEVA, O., FELDEN, B., AUDLIN, S., GESTELAND, R.F., and ATKINS, J.F. (1997). A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures. Nucleic Acids Res. 25, 5010-5016.
27. MCHUTCHISON, J.G., and FRIED, M.W. (2003). Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin. Liver Dis. 7, 149-161.
28. MIZUSHIMA, H., HIJIKATA, M., TANJI, Y., KIMURA, K., and SHIMOTOHNO, K. (1994). Analysis of N-terminal processing of hepatitis C virus nonstructural protein 2. J. Virol. 68, 2731-2734.
29. OKETANI, M., ASAHINA, Y., WU, C.H., and WU, G.Y. (1999). Inhibition of hepatitis C virus-directed gene expression by a DNA ribonuclease. J. Hepatol. 31, 628-634.
30. ROY, S., GUPTA, N., SUBRAMANIAN, N., MONDAL, T., BANERJEA, A.C., and DAS, S. (2008). Sequence-specific cleavage of hepatitis C virus RNA by DNAzymes: inhibition of viral RNA translation and replication. J. Gen. Virol. 89, 1579-1586.
31. SAKAMOTO, N., TANABE, Y., YOKOTA, T., SATOH, K., SE-KINE-OSAJIMA, Y., NAKAGAWA, M., ITSUI, Y., TASAKA, M., SAKURAI, Y., CHENG-HSIN, C., YANO, M., OHKOSHI, S., AOYAGI, Y., MAEKAWA, S., ENOMOTO, N., KOHARA, M., and WATANABE, M. (2007). Inhibition of hepatitis C virus infection and expression in vitro and in vivo by recom-binant adenovirus expressing short hairpin RNA. J. Gastro-enterol. Hepatol. 23, 1437-1447.
32. SANTIAGO, F.S., LOWE, H.C., KAVURMA, M.M., CHESTER-MAN, C.N., BAKER, A., ATKINS, D.G., and KHACHIGIAN, L.M. (1999). New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat. Med. 5, 1438.
33. SANTORO, S.W., and JOYCE, G.F. (1997). A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. USA 94, 4262-4266.
34. SCHUBERT, S., GRUNWELLER, A., ERDMANN, V.A., and KURRECK, J. (2005). Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions. J. Mol. Biol. 348, 883-893.
35. SHEPHERD, J., WAUGH, N., and HEWITSON, P. (2000). Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol. Assess. 4, 1-67.
36. SHIPPY, R., LOCKNER, R., FARNSWORTH, M., and HAMPEL, A. (1999). The hairpin ribozyme. Discovery, mechanism, and development for gene therapy. Mol. Biotechnol. 12, 117-129.
37. SOOD, V., UNWALLA, H., GUPTA, N., CHAKRABORTI, S., and BANERJEA, A.C. (2007). Potent knock down of HIV-1 replication by targeting HIV-1 Tat/Rev RNA sequences syn-ergistically with catalytic RNA and DNA. AIDS 21, 31-40.
38. STEELE, D., KERTSBURG, A., and SOUKUP, G.A. (2003). Engineered catalytic RNA and DNA: new biochemical tools for drug discovery and design. Am. J. Pharmacogenomics 3, 131-144.
39. STETSON, D.B., KO, J.S., HEIDMANN, T., and MEDZHITOV, R. (2008). Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134, 587-598.
40. SUN, L.Q., CAIRNS, M.J., GERLACH, W.L., WITHERINGTON, C., WANG, L., and KING, A. (1999). Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyr-ibozyme. J. Biol. Chem. 274, 17236-17241.
41. TAKAMIZAWA, A., MORI, C., FUKE, I., MANABE, S., MURAKAMI, S., FUJITA, J., ONISHI, E., ANDOH, T., YOSHIDA, I., and OKAYAMA, H. (1991). Structure and organization of the hepatitis C virus genome isolated from human carriers. J. Virol. 65, 1105-1113.
42. TOMEI, L., FAILLA, C., SANTOLINI, E., DE FRANCESCO, R., and LA MONICA, N. (1993). NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J. Virol. 67, 4017-4026.
43. TREPANIER, J., TANNER, J.E., MOMPARLER, R.L., LE, O.N., ALVAREZ, F., and ALFIERI, C. (2006). Cleavage of intracel-lular hepatitis C RNA in the virus core protein coding region by deoxyribozymes. J. Viral Hepat. 13, 131-138.
44. TREPANIER, J.B., TANNER, J.E., and ALFIERI, C. (2008). Reduction in intracellular HCV RNA and virus protein expression in human hepatoma cells following treatment with 2'-O-methyl-modified anti-core deoxyribozyme. Virology 377, 339-344.
45. VROLIJK, J.M., KAUL, A., HANSEN, B.E., LOHMANN, V., HAAGMANS,B.L.,SCHALM, S.W.,andBARTENSCHLAGER, R. (2003). A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J. Virol. Methods 110, 201-209.
46. WALKER, M.P., APPLEBY, T.C., ZHONG, W., LAU, J.Y., and HONG, Z. (2003). Hepatitis C virus therapies: current treatments, targets and future perspectives. Antivir. Chem. Chemother. 14, 1-21.
47. WESTERHOUT, E.M., and BERKHOUT, B. (2007). A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res. 35, 4322-4330.
48. WU, Y., YU, L., MCMAHON, R., ROSSI, J.J., FORMAN, S.J., and SNYDER, D.S. (1999). Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum. Gene Ther. 10, 2847-2857.
49. YAO, N., HESSON, T., CABLE, M., HONG, Z., KWONG, A.D., LE, H.V., and WEBER, P.C. (1997). Structure of the hepatitis C virus RNA helicase domain. Nat. Struct. Biol. 4, 463-467.
50. YOSHINAGA, T., YASUDA, K., OGAWA, Y., NISHIKAWA, M., and TAKAKURA, Y. (2007). DNA and its cationic lipid complexes induce CpG motif-dependent activation of murine dendritic cells. Immunology 120, 295-302.
51. ZEIN, N.N. (2000). Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 13, 223-235.